Mastrocola Lauren, an insider at Praxis Precision Medicines Inc (PRAX), purchased 16,234 shares at a price of $43.37 per share on November 19, 2025. The total transaction value amounted to $704,000. Following this transaction, Mastrocola holds a total of 16,234 shares in the company.
Praxis Precision Medicines is a clinical-stage biopharmaceutical firm based in Boston, Massachusetts, focusing on developing therapies for central nervous system disorders. The company, which went public on October 16, 2020, has a market capitalization of $4.7 billion and reported an earnings per share (EPS) of -12.90 for the trailing twelve months. Its product candidates include ulixacaltamide, vormatrigine, and relutrigine.
Insider transactions, such as this one, are reported to the SEC, offering transparency into the actions of company executives. While insider buying can indicate confidence in the company's future, investors should consider such activities in conjunction with broader market trends and other financial metrics. Upcoming earnings for Praxis are projected for April 30, 2026, with an EPS estimate of -3.37 and no expected revenue.